Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • News & Press
    • Press releases
  • Investors
    • Share information
    • Financial calendar
    • Financial Reports
      • Annual reports
      • Interim reports
    • Presentations
    • Business development
    • Analyst Coverage
    • Prospectuses
      • Subscription warrants
      • Rights Issue 2024
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • General meetings
Skip to content

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
6 July 2021 Scandion Oncology announces that its President & CEO has bought 10,800 shares in Scandion Oncology Download Presentation Webcast Workbook
19 May 2021 Invitation to Scandion Oncology A/S audiocast on May 20, 2021 Download Presentation Webcast Workbook
4 May 2021 Scandion Oncology welcomes Mads Aaboe Jensen as VP for Business Development and Innovation Download Presentation Webcast Workbook
30 April 2021 2021 – a transformative year for Scandion Oncology Download Presentation Webcast Workbook
21 April 2021 Interview with COO and Head of R&D Operations Maj Hedtjärn in BioStock Download Presentation Webcast Workbook
18 March 2021 Invest Talks Download Presentation Webcast Workbook
20 February 2021 Great interest at our Year-end 2020 webcast Download Presentation Webcast Workbook
18 February 2021 Invitation to Scandion Oncology A/S live webcast on February 19, 2021 Download Presentation Webcast Workbook
4 February 2021 A great milestone Download Presentation Webcast Workbook
3 February 2021 Nasdaq Stockholm Welcomes Scandion Oncology to the Nasdaq First North Growth Market Download Presentation Webcast Workbook
18 December 2020 Scandion Oncology tackles antioestrogen resistance Download Presentation Webcast Workbook
18 December 2020 Dansk lægemiddel ser ud til at bekæmpe resistens på tværs af kræftsygdomme Download Presentation Webcast Workbook
  1. Frontpage
  2. Press releases
  3. News

About us

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

News & Press

  • Press releases
  • Other news
  • Image library items
  • Video library items

Investors

  • Investors
  • Share information
  • Financial Reports
  • Presentations
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.